Compare · NIVF vs QIPT
NIVF vs QIPT
Side-by-side comparison of NewGenIvf Group Limited (NIVF) and Quipt Home Medical Corp. (QIPT): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both NIVF and QIPT operate in Misc Health and Biotechnology Services (Health Care), so they compete in similar markets.
- QIPT is the larger of the two at $166.8M, about 34.1x NIVF ($4.9M).
- Over the past year, NIVF is down 99.7% and QIPT is up 81.8% - QIPT leads by 181.5 points.
- NIVF has hit the wire 7 times in the past 4 weeks while QIPT has been quiet.
- QIPT has more recent analyst coverage (6 ratings vs 0 for NIVF).
- Company
- NewGenIvf Group Limited
- Quipt Home Medical Corp.
- Price
- $1.38-1.43%
- $3.65+0.00%
- Market cap
- $4.9M
- $166.8M
- 1M return
- -15.28%
- +2.24%
- 1Y return
- -99.74%
- +81.80%
- Industry
- Misc Health and Biotechnology Services
- Misc Health and Biotechnology Services
- Exchange
- NASDAQ
- NASDAQ
- IPO
- News (4w)
- 7
- 0
- Recent ratings
- 0
- 6
Quipt Home Medical Corp.
Quipt Home Medical Corp. provides in-home monitoring equipment and disease management services includes end-to-end respiratory solutions for patients in the United States. It offers daily and ambulatory aides; power mobility equipment; BiPAP and CPAP machines, nebulizers, oxygen concentrators, and ventilators; oxygen therapy; sleep apnea and PAP treatment equipment; and home ventilator equipment, as well as rents respiratory equipment. The company also offers management of various chronic disease states focusing on patients with heart and pulmonary disease, sleep disorders, reduced mobility, and other chronic health conditions. The company was formerly known as Protech Home Medical Corp. and changed its name to Quipt Home Medical Corp. in May 2021. Quipt Home Medical Corp. was incorporated in 1993 and is headquartered in Wilder, Kentucky.
Latest NIVF
- SEC Form 4 filed by Director Siu Wing Fung Alfred
- SEC Form 4 filed by Director Fong Hei Yue Tina
- SEC Form 6-K filed by NewGenIvf Group Limited
- NewGen’s Advanced Cytometry Platform Poised for Major UAE/GCC Expansion with Big Four Valuation of US$19 Million
- SEC Form 6-K filed by NewGenIvf Group Limited
- SEC Form 6-K filed by NewGenIvf Group Limited
- NewGen Issues 3,666,667 New Shares in Connection with Strategic K25.ai Acquisition, Reaches Milestone of US$7.6 Million Market Capitalization
- SEC Form 6-K filed by NewGenIvf Group Limited
- NewGen Increases K25.ai Ownership to 10% in Closed Pre-A Round at US$100 Million Valuation with Total US$10 Million Invested
- SEC Form 6-K filed by NewGenIvf Group Limited
Latest QIPT
- SEC Form 15-12G filed by Quipt Home Medical Corp.
- Amendment: SEC Form SCHEDULE 13D/A filed by Quipt Home Medical Corp.
- Director Wessel Brian Joseph returned $787,411 worth of shares to the company (215,729 units at $3.65), closing all direct ownership in the company (SEC Form 4)
- Chief Accounting Officer Roehrig Thomas returned $631,450 worth of shares to the company (173,000 units at $3.65), closing all direct ownership in the company (SEC Form 4)
- Chief Compliance Officer Miles Mark Alan returned $401,500 worth of shares to the company (110,000 units at $3.65), closing all direct ownership in the company (SEC Form 4)
- Director Greenberg Mark Alan returned $1,589,418 worth of shares to the company (435,457 units at $3.65), closing all direct ownership in the company (SEC Form 4)
- Exec. VP Operations Gamble Patrick Dennis returned $219,208 worth of shares to the company (60,057 units at $3.65), closing all direct ownership in the company (SEC Form 4)
- President/CEO Crawford Gregory John returned $16,755,427 worth of shares to the company (4,590,528 units at $3.65), closing all direct ownership in the company (SEC Form 4)
- Director Carter Kevin A. returned $734,234 worth of shares to the company (201,160 units at $3.65), closing all direct ownership in the company (SEC Form 4)
- Exec. VP Operations Bachelder David returned $80,869 worth of shares to the company (22,156 units at $3.65), closing all direct ownership in the company (SEC Form 4)